Business Context and Reporting Period
CareDx, Inc. (CDNA) is a precision medicine company focused on improving outcomes for transplant patients through non-invasive molecular testing, laboratory products, and digital health solutions. The company operates as a single reportable segment with headquarters in Brisbane, California, and primary operations in Omaha, Nebraska, and Stockholm, Sweden. This summary covers the fiscal year ended December 31, 2025, as reported in the Form 10-K filed on February 25, 2026.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $379.8 million | $333.8 million | +14% |
| Net Income (Loss) | ($21.4 million) | $52.5 million | Turned to loss |
| Operating Income (Loss) | ($30.8 million) | $40.8 million | ($71.5 million) |
| Cash Flow from Operations | $42.0 million | $38.0 million | +10.5% |
| Cash & Marketable Securities | $201.4 million | $260.6 million | Decrease |
| Debt | $0 | $0 | N/A |
| Accumulated Deficit | ($735.4 million) | ($626.2 million) | N/A |
Revenue Breakdown (2025): Testing services ($274.5 million), Product revenue ($48.4 million), and Patient and digital solutions ($56.9 million).
Material Changes vs. Prior Period
- Profitability Reversal: The company reported a net loss of $21.4 million in 2025 compared to net income of $52.5 million in 2024. This shift was primarily driven by a $102 million swing in litigation-related items and increased operating expenses.
- Litigation Impact: In 2024, the company recorded a $96.3 million gain due to the court invalidation of Natera patents previously found to be infringed. In 2025, the company incurred $5.7 million in litigation settlement expenses, primarily related to a securities class action settlement.
- Expense Growth: Total operating expenses increased 40% to $410.6 million. Sales and marketing expenses rose 25% ($20.7 million) due to personnel and marketing costs. General and administrative expenses decreased 14% ($17.6 million), largely due to a $25.7 million reduction in stock-based compensation.
- Revenue Growth: Testing services volume increased 14% to approximately 200,000 tests. Patient and digital solutions revenue grew 31%, driven by pharmacy sales and Ottr software adoption.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management emphasizes a strategy of "profitable growth" through solutions-selling at transplant centers to lower acquisition costs. The company is expanding its "TRANSPLANT+" initiative to enter adjacent markets such as pre-transplant assessment and autoimmune disorders. Operational excellence initiatives include investments in AI and automation.
Reimbursement Risks: Approximately 46% of testing services revenue is derived from Medicare. The company faces uncertainty regarding a proposed Local Coverage Determination (LCD) that could introduce utilization limitations and bundled payments. Additionally, a new CPT code cross-walk resulted in an $88 decrease in the reimbursement rate for AlloSure Kidney effective January 1, 2026.
Legal Contingencies:
- Natera Litigation: While the District Court invalidated Natera's patents, Natera has appealed. The company notes a potential loss of up to $96.3 million plus interest if the appeal is unsuccessful.
- DOJ/SEC Investigations: The SEC concluded its investigation in 2023 with no enforcement action. The DOJ declined to intervene in a qui tam action, though the private plaintiff's case remains pending.
- Derivative Actions: Settlements for derivative actions (Edelman and Burns) were preliminarily approved in late 2025, subject to final court approval and attorney fee negotiations.
Capital Allocation: The company repurchased $87.8 million of its common stock in 2025. As of December 31, 2025, $12.2 million remained available under the current repurchase program. Management believes existing cash and operating cash flow will meet requirements for the next 12 months.
Investor Verification Checklist
- Reimbursement Policy Changes: Verify the finalization of the proposed MolDX/Noridian LCD and its potential impact on test volume and revenue per test.
- Litigation Outcomes: Monitor the status of the Natera patent appeal and the final approval of the securities class action and derivative action settlements.
- Stock-Based Compensation: Assess the sustainability of the significant reduction in stock-based compensation expense ($34.9 million in 2025 vs. $66.4 million in 2024) and its impact on future GAAP profitability.
- Operational Cash Flow: Confirm that operating cash flow remains positive despite the net loss, driven by non-cash adjustments and working capital management.
- Internal Controls: Note that the material weakness in internal controls over financial reporting (related to stock-based compensation) identified in 2024 was remediated in 2025.